InterStim® Amplitude Study

NCT ID: NCT03335761

Last Updated: 2021-01-08

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

97 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-27

Study Completion Date

2019-11-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This feasibility study will explore the effects of three different InterStim amplitude settings on overactive bladder symptoms (OAB).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, randomized, multicenter, single-blinded study to explore the efficacy and quality of life (QoL) of 3 different amplitude settings.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Urge Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Amplitude Setting #1

InterStim Therapy will be set to amplitude parameter #1.

Group Type EXPERIMENTAL

InterStim Therapy

Intervention Type DEVICE

Device Programming

Amplitude Setting #2

InterStim Therapy will be set to amplitude parameter #2.

Group Type EXPERIMENTAL

InterStim Therapy

Intervention Type DEVICE

Device Programming

Amplitude Setting #3

InterStim Therapy will be set to amplitude parameter #3.

Group Type EXPERIMENTAL

InterStim Therapy

Intervention Type DEVICE

Device Programming

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

InterStim Therapy

Device Programming

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Primary diagnosis of urinary urge incontinence (UUI) as demonstrated on a 3-day baseline voiding diary demonstrating at least 3 UUI episodes
2. Female subjects 18 years of age or older
3. Candidate for InterStim Lead Placement
4. Willing and able to accurately complete voiding diaries, questionnaires, attend visits, and comply with the study protocol (which includes maintenance of InterStim II programming settings over the course of the study)
5. Willing and able to provide signed and dated informed consent
6. Willing to maintain current regimen (dosage and frequency) of any overactive bladder (OAB) medication

Exclusion Criteria

1. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury
2. History of diabetes unless the diabetes is well-controlled through diet and/or medications
3. Symptomatic urinary tract infection (UTI)
4. Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component
5. Treatment of urinary symptoms with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study
6. Implanted with a neurostimulator, pacemaker, or defibrillator
7. Have knowledge of planned MRIs, diathermy, microwave exposure, high output ultrasonic exposure, or radio frequency (RF) energy exposure not included within the scanning conditions provided with the MRI Guidelines for InterStim Therapy
8. Women who are pregnant or planning to become pregnant
9. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements.
10. Currently enrolled or planning to enroll in a potentially confounding clinical study during the course of the study (co-enrollment in concurrent studies is only allowed when documented pre-approval is obtained from the Medtronic study manager (or designee).
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

MedtronicNeuro

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Academic Urology & Urogynecology of Arizona

Phoenix, Arizona, United States

Site Status

East Coast Institute for Research

Jacksonville, Florida, United States

Site Status

Pinellas Urology

St. Petersburg, Florida, United States

Site Status

Florida Urology Partners

Tampa, Florida, United States

Site Status

Minnesota Urology Fridley

Fridley, Minnesota, United States

Site Status

Minnesota Urology Woodbury

Woodbury, Minnesota, United States

Site Status

Adult Pediatric Urology and Urogynecology

Omaha, Nebraska, United States

Site Status

Urologic Research & Consulting

Englewood, New Jersey, United States

Site Status

Carolina Urology Partners

Concord, North Carolina, United States

Site Status

Chattanooga Hamilton County Hospital Authority d/b/a Erlanger Health System

Chattanooga, Tennessee, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

Aurora Research Institute - Aurora West Allis Women's Pavilion

West Allis, Wisconsin, United States

Site Status

UZ Leuven - Campus Gasthuisberg - Department Urology

Leuven, , Belgium

Site Status

University Urology Associates, Toronto Western Hospital

Toronto, Ontario, Canada

Site Status

CHU Hôpitaux de Rouen - Hôpital Charles Nicolle

Rouen, , France

Site Status

Azienda Ospedaliera Universitaria Integrata Verona

Verona, , Italy

Site Status

Erasmus MC

Rotterdam, , Netherlands

Site Status

University College London Hospitals NHS Foundation Trust - University College Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Canada France Italy Netherlands United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MDT17030

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.